Upgrade to SI Premium - Free Trial

CRISPR Therapeutics (CRSP) PT Raised to $110 at Piper Sandler

March 17, 2026 7:12 AM
Piper Sandler analyst Edward A. Tenthoff raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $110.00 (from $105.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change